Kanjinti Injection
Generic name:trastuzumab-anns
Dosage form: injection, powder, lyophilized, for solution
Medically reviewed by Drugs.com. Last updated on Sep 21, 2021.
On This Page
- Boxed Warning
- Indications and Usage
- Dosage and Administration
- Dosage Forms and Strengths
- Contraindications
- Warnings and Precautions
- Adverse Reactions/Side Effects
- Drug Interactions
- Use In Specific Populations
- Overdosage
- Description
- Clinical Pharmacology
- Nonclinical Toxicology
- Clinical Studies
- How Supplied/Storage and Handling
- Patient Counseling Information
Cardiomyopathy
Trastuzumab productsadministration can result in sub-clinical and clinical cardiac failure. The incidence and severity was highest in patients receivingtrastuzumabwith anthracycline-containing chemotherapy regimens.
Evaluate left ventricular function in all patients prior to and during treatment withKANJINTI. DiscontinueKANJINTItreatment in patients receiving adjuvant therapy and withholdKANJINTIin patients with metastatic disease forclinically significant decrease in left ventricular function[see Dosage and Administration(2.3)andWarnings and Precautions (5.1)].
Infusion Reactions; Pulmonary Toxicity
Trastuzumab productsadministration can result in serious and fatal infusion reactions and pulmonary toxicity. Symptoms usually occur during or within 24 hours of admini...
